An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease
Neuronal ceroid lipofuscinosis type-2 (CLN2) disease is a rare, autosomal recessive, pediatric-onset, neurodegenerative lysosomal storage disease caused by mutations in the TPP1 gene. Cerliponase alfa (Brineura®), a recombinant form of human tripeptidyl peptidase-1, was recently developed as a treat...
Main Authors: | Kathleen W. Wyrwich PhD, Angela Schulz MD, Miriam Nickel MD, Peter Slasor ScD, Temitayo Ajayi MD, David R. Jacoby MD, PhD, Alfried Kohlschütter MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SciELO
2018-07-01
|
Series: | Journal of Inborn Errors of Metabolism and Screening |
Online Access: | https://doi.org/10.1177/2326409818788382 |
Similar Items
-
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
by: Yosuke Kagawa, MD, et al.
Published: (2023-03-01) -
Perceived Behavioral Control as a Key to Integrative Medicine
by: Stephen R. Shamblen PhD, et al.
Published: (2018-10-01) -
Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials
by: Miriam Nickel, et al.
Published: (2022-02-01) -
Hypnosis Influence on the Perfusion in Perforator Flaps in Early Postoperative Period: A Series of 18 Cases
by: Pavlo O. Badiul, MD, PhD, ScD, et al.
Published: (2019-11-01) -
Age at asthma diagnosis is related to prevalence and characteristics of asthma symptoms
by: Hanna Hisinger-Mölkänen, MD, et al.
Published: (2022-09-01)